New issues on measurement of B-type natriuretic peptides

What is it about?

Clinicians should accurately consider both the clinical setting of patients and the analytical characteristics of immunoassays in order to correctly interpret the variations of natriuretic peptides measured by commercially available laboratory methods, especially in patients treated with the new drug class of angiotensin receptor-neprilysin inhibitors (ARNi).

Featured Image